Entera Bio Ltd. (ENTX) · Aug 7, 2026 · Company update

Phase 3 funding and FDA alignment confirmed, but quarterly loss missed expectations

Phase 3 funding and FDA alignment confirmed, but quarterly loss missed expectations

The strategic outcome was already largely expected. The FDA’s alignment with a 12-month registrational Phase 3 design and the $275 million private placement were announced before this filing—FDA feedback on June 22, 2026, and the financing on July 27, 2026—so the 8-K mainly confirms rather than newly changes the investment case. The financing is expected to fund EB613 through topline Phase 3 results and an anticipated NDA submission, with operations supported into 2030 (Cash and cash equivalents).

The reported quarterly loss was worse than the published expectation. Net loss was $0.14 per share versus a published consensus of approximately $0.09 per share loss, a miss of about $0.05 per share.

MetricQ2 2026Q2 2025 / expectation
Net loss per share$0.14 loss (Net loss)$0.06 loss prior year (Net loss); ~$0.09 loss published consensus
Net loss$7.3 million loss (Net loss)$2.7 million loss prior year (Net loss)
Research and development expense$3.2 million (Research and development expenses)$1.5 million prior year (Research and development expenses)
Cash and cash equivalents$11.3 million (Cash and cash equivalents)$275.0 million gross financing proceeds announced in July; pro forma runway into 2030 (Cash and cash equivalents)

The EPS miss is less alarming than the headline suggests. The filing attributes $2.7 million of the loss increase to a non-cash fair-value remeasurement of pre-funded warrants issued in April, while the higher research spending reflects preparation for EB613’s Phase 3 program and the OPKO collaboration (Net loss; Research and development expenses). That makes the miss financially unfavorable versus expectations, but not evidence of an equivalent deterioration in the underlying development program.

The net read is mixed: execution is funded, but little new upside was added today. The company now has substantially more financing visibility and a stated path toward Phase 3 and an NDA, but both the regulatory alignment and capital raise were already public. Against that standing expectation, the filing contributes a quarterly earnings miss and confirmation of increased spending, offset by a stronger balance-sheet position and no reported setback to EB613’s registrational plan.

Original filing on SEC EDGAR

More Entera Bio Ltd. news

Phase 3 funding and FDA alignment confirmed, but quarterly loss missed expectations | ENTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.